Ceptaris Therapeutics Receives EMA Orphan Drug Designation for Proprietary Mechlorethamine Gel

By WebmasterJanuary 18, 2012November 1st, 2024No Comments

Ceptaris Therapeutics Receives EMA Orphan Drug Designation for Proprietary Mechlorethamine Gel
Read more here

Previous PostNiiki Pharma Forms Scientific Advisory Board with Leading U.S. Oncologists
Next PostNiiki Pharma Announces the Completion of Phase I Dose Escalation for First-in-Man Anti-Cancer Agent NKP-1339